ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492

Its studies are mostly in Lupus Erythematosus, Systemic, led by AstraZeneca.

Furthest: phase 2, since Jul 29, 20242 company-led studies, 2 open or runningNext primary completion: May 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 2since Jul 29, 2024Jul 29, 2024May 5, 2027phase 1 · NCT06916806
  • Named in AstraZeneca’s own pipeline as AZD5492, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2024First study: phase 2 study in RecurrenceFirst studyNCT06542250 · 174 planned · United States, Australia, Canada and more
  2. Mar 13, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06916806 · 72 planned · United States, Canada, China and more

Ahead

  1. May 5, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06916806
  2. Dec 18, 2029Primary completion: phase 2 study in RecurrenceNCT06542250

TargetBeta

“A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3/anti-CD8 trispecific anti…”NCIt, read by Claude
“A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06916806Lupus Erythematosus, Systemic · United States, Canada, China and more1RecruitingMay 5, 202772
NCT06542250Recurrence · United States, Australia, Canada and more2RecruitingDec 18, 2029174

How it is read

Names in the registry

  • “AZD5492”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.